GleamWall
中文EN

OGEN ORAGENICS INC

Pharmaceutical Preparations · NYSE · SEC CIK 1174940 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY11.8%
TTM EPS YoY-102.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-176.1%
ROA-120.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets66.7%
Debt / equity0.00x
Current ratio—
Interest coverage-547.81x

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$2.39M$4.11M
SG&A expense$6.97M$6.44M
Operating income-$9.36M-$10.56M
Interest expense$785,930$29,828
Pretax income-$9.98M-$10.57M
Income tax-$136,910—
Net income-$9.84M-$10.57M
EPS (basic)-4.56-47.88
EPS (diluted)-4.56-47.88
Weighted avg. shares (diluted)2.16M220,731
Balance sheet
Cash & equivalents$4.40M$864,840
Short-term investments$4.00M—
Current assets$10.07M$1.47M
Total assets$10.07M$1.47M
Total liabilities$1.79M$1.68M
Shareholders' equity$8.28M-$211,885
Shares outstanding4.27M419,003
Cash flow statement
Operating cash flow-$9.25M-$8.60M
Financing cash flow$16.78M$5.98M
Stock-based compensation$642,364$516,049

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.